USSTOCK.TODAY
Market Closed
Log in Sign up

Cerenome Announces Interim Clinical Data for REYOBIQ in Patients with Leptomeningeal Metastases

InvestorsHub +1 · ·by G4L

CNSY
CNSY Cerenome Inc
$0.63 -11.82%
View chart & analysis →
  1. 1Cerenome, Inc. announced interim clinical data for REYOBIQ involving 10 patients with leptomeningeal metastases through the ReSPECT-LM study.
  2. 2Analysis showed nausea occurred in 60% of patients, headaches in 40%, and decreases in lymphocyte and white blood cell counts were observed in 40% of participants.
  3. 3Cerenome aims to initiate a Phase 2 randomized controlled trial for REYOBIQ in 2027.

So what's the key point?

Cerenome shared interim test results for a drug targeting patients with leptomeningeal metastases. Side effects such as nausea were identified in 60% of patients.

Source InvestorsHub +1 · View original ↗

Today's 5 AI picks, all free
Nothing hidden: past picks and how they did against the S&P 500.
See today's picks →